Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-11-12
1999-12-21
Jones, Dwayne C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514326, A01N 4342
Patent
active
060049707
ABSTRACT:
Nicotine dependency is treated by administration of an opioid antagonist. In some embodiments, rapid or ultra rapid detoxification techniques include using a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone or naltrexone or a mixture of any one of these, and either clonidine or related compounds either while awake, or while under sedation or anesthesia, followed by continued administration of an effective amount of an opioid antagonist with or without agents that enhance nicotine dependency treatment. Persons are also treated for nicotine dependency with more gradual detoxification methods using administration of a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone, naltrexone, or a mixture of any of these, and an effective amount of agents used to treat nicotine withdrawal including nicotine, such as that delivered by a nicotine patch, nicotine chewing gum, nicotine inhaler or other methods for delivering nicotine, antidepressants and antianxiety agents, and/or clonidine and related compounds. Administration of an effective amount of an opioid antagonist to prevent relapse, attenuate craving, and reduce weight gain during and after treatment for nicotine dependency is continued in some embodiments.
REFERENCES:
patent: 4946848 (1990-08-01), Tuttle et al.
patent: 5422356 (1995-06-01), Zimmerman et al.
patent: 5486362 (1996-01-01), Kitchell et al.
Abstract to Lee et al, "Cigarette Smoking, nicotine addiction, and its pharmacolgic treatment.", Archives of Internal Medicine, 153/1, pp. 34-48, 1993.
Karras et al., "Naloxone Reduces Cigarette Smoking", Life Sciences vol. 27, No. 17., pp. 1541-1545, 1980.
Aceto, et al., Neuropharmacol. 25:1031-1036 (1986).
Covey & Glassman, Br. J. Addiction 86:991-998 (1991).
Davenport, et al., Neurosci. Lett. 113:40-46 (1990).
Davison, et al., Clin. Pharmacol. Ther. 44:265-267 (1988).
Franks, et al., J.A.M.A. 262:3011-3013 (1989).
Glassman, et al., J.A.M.A. 259:2863-2866 (1988).
Gorelick, et al., J. Subst. Abuse 1:153-159 (1989).
Hilleman, et al., Ann. Pharmacother. 27:1025-1028 (1993).
Hollt & Horn, Clin. Investig. 70:224-231 (1992).
Houdi, et al., Peptides 12:161-166 (1990).
Hutchinson, et al., Exp. Clin. Psychopharm. 4:431-437 (1996).
Karras & Kane, Life Sci. 27:1541-1545 (1980).
Malin, et al., Psychopharm. 112:339-342 (1993).
Malin, et al., Pharm. Biochem. & Behav. 53:81-85 (1996).
Nemeth-Coslett & Griffiths, Psychopharm. 89:261-264 (1986).
O'Connor, et al., J.G.I.M., 10:255-260 (1995).
Opitz & Weischer, Drug & Alc. Dep. 21:99-104 (1988).
Pauli, et a., Psychopharm. 111:472-476 (1993).
Pierzchala, et al., Peptides 8:1035-1043 (1987).
Pomerleau, et al., Add. Behav. 9:265-271 (1984).
Prochazka, et al., Arch. Intern. Med. 152:2065-2069 (1992).
Sutherland, et al., Psychopharm. 120:418-425 (1995).
Swan, et al., Add. Behav. 21: 481-490 (1996).
Tripathi, et al., J. Pharm. Exp. Ther. 221:91-96 (1982).
Krishnan-Sarin Suchitra
Meandzija Boris
O'Connor Patrick G.
O'Malley Stephanie
Jones Dwayne C.
Krinsky Mary M.
Yale University
LandOfFree
Smoking cessation treatments using naltrexone and related compou does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Smoking cessation treatments using naltrexone and related compou, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Smoking cessation treatments using naltrexone and related compou will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-505438